A fully synthetie candidate meningococcal vaccine will be developed which is composed of a synthetic carbohydrate B-epitope derived from meningococcal LPS, a synthetic peptide T-epitope and a lipopeptide. The synthetic methodology will be of general importance for synthetic carbohydrate-based vaccine development.
The physical properties of the glycoconjugates will be studied by eleetron microscopy.
The conjugates will be tested for T-cell recognition and experiments will be performed with peripheral blood mononucleated cells from HLA-typed volunteers. The conjugates will be used to evoke antibodies in mice and the T-cell-dependent properties of these antibodies will be examined. The antibodies will be determined by ELISA inhibition studies. The research will also provide a further understanding of the requirements for the induction of relevant T-helper reponce.